Literature DB >> 6260268

Hereditary myeloperoxidase deficiency.

M Kitahara, H J Eyre, Y Simonian, C L Atkin, S J Hasstedt.   

Abstract

Subjects with neutrophil myeloperoxidase (MPO) deficiency have been rarely reported. In part this may be due to the lack of a simple screening technique that would detect them. With the routine use of a cytochemical leukocyte differential counter that employs MPO stains, over a 40-mo a period 8 unrelated probands with partial MPO-deficiency and one with complete deficiency were identified. Family studies have identified 23 additional, partially deficient subjects. The largest pedigrees demonstrate that the carrier state or partial MPO deficiency is inherited in an autosomal dominant pattern. Leukocytes from a subject with complete MPO deficiency and from some subjects with partial deficiency have impaired bactericidal activity against S. aureus. Superoxide generation was increased and chemiluminescence decreased in MPO-deficient leukocytes. Eleven subjects were prospectively followed for 18-30 mo. Only two partially deficient subjects have had serious infections consisting of recurrent streptococcal cellulitis and aseptic meningitis. These data suggest that leukocyte MPO deficiency is a common inherited defect that results in minimal clinical problems, supporting the concept of multiple leukocyte bacterial killing systems.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260268

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Photon emission of phagocytes in relation to stress and disease.

Authors:  E M Lilius; P Marnila
Journal:  Experientia       Date:  1992-12-01

Review 2.  Role of oxidants in microbial pathophysiology.

Authors:  R A Miller; B E Britigan
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 3.  Myeloperoxidase in human neutrophil host defence.

Authors:  William M Nauseef
Journal:  Cell Microbiol       Date:  2014-06-19       Impact factor: 3.715

4.  A case of eosinophil peroxidase deficiency.

Authors:  D Kutter; S Mueller-Hagedorn; T Forges; R Glaesener
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

5.  Defective bactericidal activity and absence of specific granules in neutrophils from a patient with recurrent bacterial infections.

Authors:  D R Ambruso; M Sasada; H Nishiyama; A Kubo; A Komiyama; R H Allen
Journal:  J Clin Immunol       Date:  1984-01       Impact factor: 8.317

6.  Lactoferrin-deficient neutrophil polymorphonuclear leucocytes in leukaemias: a semiquantitative and ultrastructural cytochemical study.

Authors:  J Miyauchi; Y Watanabe; Y Enomoto; K Takeuchi
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

7.  Characterization of cDNA clones for human myeloperoxidase: predicted amino acid sequence and evidence for multiple mRNA species.

Authors:  K R Johnson; W M Nauseef; A Care; M J Wheelock; S Shane; S Hudson; H P Koeffler; M Selsted; C Miller; G Rovera
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

8.  Decreased luminol-dependent chemiluminescence response of neutrophils to recombinant human tumour necrosis factor in patients with gastric cancer.

Authors:  I A Schepetkin; N V Cherdyntseva; E V Borunov; I L Skutina; S A Naumov
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 9.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

10.  Cytochemically unreactive neutrophils from subjects with myeloperoxidase (MPO) deficiency show a complex pattern of immunoreactivity with anti-MPO monoclonal antibodies: a flow cytometric and immunocytochemical study.

Authors:  F Lanza; A Latorraca; P Musto; L Ferrari; S Moretti; G Zabucchi; M Carotenuto; G L Castoldi
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.